IASO BIO and Umoja Biopharma Establish a Novel Partnership for Advancing Ex Vivo and In Vivo Cell and Gene Therapies

IASO Biotherapeutics ("IASO Bio") and Umoja Biopharma, Inc. ("Umoja") have recently announced a strategic collaboration to advance the development and commercialization of innovative cell and gene therapies. Specializing in cell therapies and antibody products, IASO Bio will gain exclusive access to Umoja's rapamycin-activated cytokine receptor (RACR™) platform, a synthetic cytokine receptor technology. This collaboration will focus on the development of two ex vivo induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR)-bearing cell therapies.

IASO Bio will undertake responsibilities for worldwide product development, manufacturing, regulatory processes, and commercialization for both ex vivo products. In return, Umoja will be granted exclusive rights to CAR cassettes for two targets, enabling the advancement of two in vivo product candidates utilizing VivoVec™, Umoja's proprietary lentiviral in vivo gene delivery technology. Umoja will handle product development, manufacturing, regulatory matters, and commercialization outside of Greater China, while IASO Bio will manage these aspects within the Greater China territory. Both parties will be entitled to customary development and sales milestones as well as royalties related to the collaborations.

The collaboration aims to propel the development of off-the-shelf cell and gene therapies, leveraging innovative scientific advancements with applications in oncology and immunology. Alan Fu, Chief Financial Officer of IASO Bio, expressed excitement about the collaboration, highlighting the potential of combining Umoja's RACR platform with IASO's validated CAR constructs to deliver novel allogeneic treatments globally. Umoja's Chief Operating and Chief Business Officer, David Fontana, PhD, emphasized the shared commitment to making cell therapies more accessible, stating that the collaboration goes beyond traditional approaches to maximize the potential of CAR-T cell therapies. The incorporation of IASO's CARs with Umoja's VivoVec technology holds the promise of expanding the reach of in vivo gene delivery technology into new indications and offering additional options for patients in need.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!